Novel Therapies in Lung Cancer
Originally presented at HOPA's 13th Annual Conference, March 2017.
Lung cancer is the leading cause of cancer-related death in the United States. With the approval of novel targeted therapies and immunotherapy, the treatment landscape for lung cancer patients has changed dramatically. The use of these agents has dramatically improved survival and quality of life in patients with advanced or metastatic non–small cell lung cancer or extensive-stage small cell lung cancer. This session will review targeted and immunotherapy agents that are used in lung cancer treatment, current guideline recommendations, and outcome data comparing these novel agents to the standard-of-care regimens.
- Describe the role of various signaling pathways involved in the development and progression of lung cancer.
- Review current treatment options for the treatment of squamous cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC).
- Discuss available data for the use of targeted therapies and immunotherapy in the management of metastatic NSCLC.
Eve Segal, PharmD BCOP
Eve Segal is a clinical oncology pharmacist at the University of Washington/Seattle Cancer Care Alliance. Her professional responsibilities include working in a variety of multidisciplinary solid-tumor clinics at the Seattle Cancer Care Alliance and precepting both PGY-1 and PGY-2 residents on their outpatient thoracic rotations. She also serves as a clinical instructor at the University of Washington School of Pharmacy. She received her PharmD degree from the Massachusetts College of Pharmacy Health Sciences University in Boston, MA, and completed her oncology specialty residency at St. Luke’s Mountain States Tumor Institute in Boise, ID.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020